NASDAQ:MBRX Moleculin Biotech (MBRX) Stock Price, News & Analysis $6.83 -0.31 (-4.34%) Closing price 03:59 PM EasternExtended Trading$6.96 +0.14 (+1.98%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Moleculin Biotech Stock (NASDAQ:MBRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Moleculin Biotech alerts:Sign Up Key Stats Today's Range$6.81▼$7.5050-Day Range$5.30▼$16.6052-Week Range$3.23▼$227.05Volume11,980 shsAverage Volume42,231 shsMarket Capitalization$7.24 millionP/E RatioN/ADividend YieldN/APrice Target$60.00Consensus RatingHold Company Overview Moleculin Biotech is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing treatments for cancer and other serious diseases. Its research centers on drug candidates intended to address cancers that can be difficult to treat with existing therapies. The company’s pipeline includes Annamycin, an investigational anthracycline being studied for acute myeloid leukemia and soft-tissue sarcoma that has spread to the lungs. Moleculin has described Annamycin as designed to avoid some limitations associated with older anthracyclines, including heart-related toxicity. Another candidate, WP1066, is an investigational immunotherapy designed to inhibit STAT3, a protein involved in tumor growth and immune response. It is being explored for brain tumors, including glioblastoma. Moleculin is led by co-founder and Chief Executive Officer Walter Klemp. Its drug candidates remain investigational and are not approved for commercial use.AI Generated. May Contain Errors. Read More Moleculin Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreMBRX MarketRank™: 3.459387483355 of 5 starsMoleculin Biotech scored higher than 69% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingMoleculin Biotech has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialMoleculin Biotech has a consensus price target of $60.00, representing about 778.5% upside from its current price of $6.83.Amount of Analyst CoverageMoleculin Biotech has only been the subject of 2 research reports in the past 90 days.Read more about Moleculin Biotech's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Moleculin Biotech are expected to grow in the coming year, from ($47.40) to ($23.10) per share.Price to Book Value per Share RatioMoleculin Biotech has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.48% of the float of Moleculin Biotech has been sold short.Short Interest Ratio / Days to CoverMoleculin Biotech has a short interest ratio ("days to cover") of 0.81, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Moleculin Biotech has recently decreased by 56.82%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMoleculin Biotech does not currently pay a dividend.Dividend GrowthMoleculin Biotech does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment0.16 News SentimentMoleculin Biotech has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Moleculin Biotech this week, compared to 3 articles on an average week.Search Interest3 people have searched for MBRX on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Moleculin Biotech to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Moleculin Biotech insiders have not sold or bought any company stock.Percentage Held by Insiders18.04% of the stock of Moleculin Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions15.52% of the stock of Moleculin Biotech is held by institutions.Read more about Moleculin Biotech's insider trading history. Receive MBRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MBRX Stock News HeadlinesMoleculin Reports Q3 Results; Completes MIRACLE Trial Treatment With Data Expected In Q1 2027November 16 at 4:03 PM | rttnews.comMoleculin Biotech Reports Third Quarter 2026 Financial Results as Pivotal MIRACLE Trial Advances Toward Key Q1 2027 Data ReadoutNovember 16 at 7:30 AM | globenewswire.comDon’t delete this, read it todayPorter Stansberry has spent more than 30 years studying the economy and financial markets, and says he has never felt pressure like this. He believes the foundations beneath our way of life have cracked. One Nobel Prize winner has warned that the force behind it threatens to divide America. Stansberry points to rising living costs, deepening division and building anger as signs. His documentary, The Final Displacement, names the force and outlines what he believes you can do about it now.November 17 at 1:00 AM | Porter & Company (Ad)Moleculin Secures Australian Patent for Annamycin Formulation TechnologyNovember 12, 2026 | globenewswire.comPreclinical Data Show Annamycin Makes Pancreatic Cancer Responsive to Checkpoint Inhibitors, Opening a Combination Path with ImmunotherapiesNovember 10, 2026 | globenewswire.comMoleculin Biotech (NASDAQ:MBRX) Stock Gets Downgrade from Wall Street ZenNovember 7, 2026 | americanbankingnews.comMoleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual MeetingNovember 4, 2026 | globenewswire.comMoleculin Completes Dosing In Part A Of Pivotal MIRACLE Trial; Data Readout Expected In Q1 2027October 31, 2026 | rttnews.comSee More Headlines MBRX Stock Analysis - Frequently Asked Questions How have MBRX shares performed this year? Moleculin Biotech's stock was trading at $66.20 at the beginning of the year. Since then, MBRX shares have decreased by 89.7% and is now trading at $6.83. How were Moleculin Biotech's earnings last quarter? Moleculin Biotech, Inc. (NASDAQ:MBRX) issued its quarterly earnings data on Friday, November, 13th. The company reported ($9.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($8.87) by $0.72. When did Moleculin Biotech's stock split? Moleculin Biotech's stock reverse split on Monday, December 1st 2025.The 1-25 reverse split was announced on Wednesday, November 26th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, November 28th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Moleculin Biotech IPO? Moleculin Biotech (MBRX) raised $8 million in an initial public offering on Thursday, June 2nd 2016. The company issued 1,540,026 shares at $5.00-$6.00 per share. How do I buy shares of Moleculin Biotech? Shares of MBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Moleculin Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Moleculin Biotech investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Micron Technology (MU), NIO (NIO), Intel (INTC) and Tesla (TSLA). Company Calendar Last Earnings11/13/2026Today11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 MBRX's financial health is in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:MBRX CIK1659617 Webwww.moleculin.com Phone(713) 300-5160FaxN/AEmployees17Year Founded2006Price Target and Rating Average Price Target for Moleculin Biotech$60.00 High Price Target$60.00 Low Price Target$60.00 Potential Upside/Downside+778.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($142.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$33.56 million Net MarginsN/A Pretax MarginN/A Return on Equity-50.00% Return on Assets-32.22% Debt Debt-to-Equity RatioN/A Current Ratio1.37 Quick Ratio0.94 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$13.65 per share Price / Book0.50Miscellaneous Outstanding Shares1,060,000Free Float842,000Market Cap$7.24 million OptionableNot Optionable Beta2.11 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:MBRX) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...Porter & Company | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.